Cryopreservation Options to Preserve Fertility in Female Cancer Patients: Available Clinical Practice and Investigational Strategies from the Oncology Guidelines Point of View

• Main Authors: Leila Mirzaeian, Haniyeh Rafipour, Saadeh Hashemi, Sara Zabihzadeh, Saeid Amanpour
• Format: Article
• Language: English
• Published: Tehran University of Medical Sciences 2020-08-01
• Series: Basic & Clinical Cancer Research
• Subjects: Oncology guidelines; cancer treatment; fertility preservation; cryopreservation.
• Online Access: https://bccr.tums.ac.ir/index.php/bccrj/article/view/337
• ISSN: 2228-6527; 2228-5466

  In recent years, advances in cancer treatment have improved the survival rate of cancer patients significantly. However, destructive damage to ovaries due to the therapies or cancer itself can cause different degrees of infertility in women of reproductive age that can affect their quality of life seriously. In this study, fertility cryopreservation options for female cancer patients in oncology guidelines were reviewed. Cryopreservation methods have a long history in reproductive biology and oncology. However, embryo and oocyte cryopreservation were the eligible restoration strategies in clinical oncology practice. Ovarian tissue cryopreservation (OTC) is the latest option recommended for fertility preservation in pre-pubertal and adult patients who cannot delay their treatment or in whom taking IVF hormones may have adverse effects on their cancer. Reports show that frozen-thawed ovarian tissue transplantation has led to more than 130 live births so far in patients, most of whom were cancer patients. Although OTC is indeed generally recognized as an investigational method, it is recommended in some important guidelines, such as ASCO 2018. Therefore, based on many clinical pieces of evidence, it is predicted that the investigational label will soon be removed, and OTC might be considered as one of the main fertility preservation options for female cancer patients in clinical oncology practice.